Stryker Corporation 10-Q Summary: Period Ended September 30, 2006
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2006, and the nine-month period ended on that date. Stryker Corporation is a leading medical technology company with operations in Orthopaedic Implants and MedSurg Equipment. The company operates globally, with domestic sales accounting for 66% of total revenues in the first nine months of 2006. The financial statements reflect the adoption of FASB Statement No. 123 (revised) regarding share-based payments, effective January 1, 2006.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 | Units |
|---|---|---|---|
| Net Sales | $1,294.0 | $3,942.8 | Millions |
| Gross Profit | $852.3 | $2,595.7 | Millions |
| Gross Margin | 65.9% | 65.8% | Percentage |
| Operating Income | $254.4 | $768.4 | Millions |
| Net Earnings | $188.4 | $549.8 | Millions |
| Diluted EPS | $0.46 | $1.34 | Per Share |
| Cash from Operations | $280.4 | $496.9 | Millions |
| Cash and Equivalents | $182.7 | $182.7 | Millions (Sep 30) |
| Marketable Securities | $902.7 | $902.7 | Millions (Sep 30) |
| Total Debt (Current + Long-Term) | $15.2 | $15.2 | Millions (Sep 30) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% year-over-year for both the quarter and the nine-month period. Domestic sales grew 11%, while international sales grew 7-8% (9-7% on a constant currency basis).
- Profitability: Net earnings for the quarter surged 56% to $188.4 million, and 18% for the nine-month period to $549.8 million. This growth was driven by higher unit volumes, improved selling prices, and lower effective tax rates compared to 2005.
- One-Time Charges: The nine-month 2006 results included a $52.7 million charge for purchased in-process research and development (IPR&D) related to the acquisition of Sightline Technologies. The 2005 comparison period included a $31.3 million tax charge related to the repatriation of foreign earnings.
- Working Capital: Working capital increased by $382.0 million to $2,003.3 million. Days sales outstanding increased to 59 days, and days sales in inventory increased to 138 days, attributed to slower collections and inventory buildup for new product launches.
Guidance, Outlook, and Risks
- 2006 Outlook: Management projects diluted net earnings per share of $1.89 for the full year 2006, a 20.4% increase over 2005. Adjusted diluted EPS (excluding the Sightline IPR&D charge) is projected at $2.02. Net sales are expected to increase approximately 11%.
- 2007 Outlook: The company projects diluted net earnings per share of approximately $2.42 for 2007.
- Acquisition Integration: The company expects to complete the development of Sightline's flexible endoscope technologies and commercialize initial products in 2007. Potential risks include regulatory delays and clinical trial issues.
- Legal and Regulatory: The company is cooperating with Department of Justice investigations regarding billing practices (Physiotherapy Associates) and potential antitrust violations related to orthopaedic implants. No material losses are anticipated beyond amounts already provided.
- Accounting Changes: The company plans to adopt FASB Interpretation No. 48 (Income Taxes) in 2007 and FASB Statement No. 158 (Pension Plans) by December 31, 2006. The latter may result in the recognition of an additional $21.3 million non-current liability.
Investor Verification Checklist
- Verify the impact of the $52.7 million Sightline IPR&D charge on 2006 earnings and the timeline for product commercialization in 2007.
- Monitor the status of Department of Justice investigations regarding billing practices and antitrust laws.
- Assess the sustainability of the 11% sales growth given potential pricing pressures in the U.S. and international markets.
- Review the effectiveness of inventory management as days sales in inventory increased significantly to 138 days.
- Confirm the impact of the upcoming adoption of FASB Interpretation No. 48 on future effective tax rates.